首页> 外国专利> RECOMBINANT ENDOTHELIAL CELL GROWTH INHIBITORS DERIVED FROM A MAMMALIAN PLASMINOGEN

RECOMBINANT ENDOTHELIAL CELL GROWTH INHIBITORS DERIVED FROM A MAMMALIAN PLASMINOGEN

机译:哺乳动物纤溶酶原来源的重组内皮细胞生长抑制剂

摘要

Proteolytic enzymes are involved in generation of a number of endogenous angiogenesis inhibitors and it has been shown that urokinase-activated plasmin can process plasminogen to release an angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5). However, this proteolytic protein (proteolytic K1-5) cannot be secreted (exported) from cells and thus is limited in its application as a therapeutic. The present inventors have now engineered a recombinant protein derived from plasminogen which is folded correctly such that it can be secreted from cells in which it is expressed. The inventors surprisingly found that in order to fold correctly such that it can be secreted, the recombinant protein must comprise a secretory signal peptide and a pre-activation peptide derived from plasminogen.
机译:蛋白水解酶参与许多内源性血管生成抑制剂的产生,并且已经显示,尿激酶活化的纤溶酶可以加工纤溶酶原以释放血管生成抑制剂K1-5(蛋白酶活化的环1-5)。然而,该蛋白水解蛋白(蛋白水解K1-5)不能从细胞分泌(输出),因此在其作为治疗剂的应用方面受到限制。本发明人现在已经工程化了从纤溶酶原衍生的重组蛋白,其被正确折叠以使得它可以从表达它的细胞中分泌出来。发明人惊奇地发现,为了正确折叠以使其可以被分泌,重组蛋白必须包含分泌信号肽和源自纤溶酶原的预激活肽。

著录项

  • 公开/公告号WO0220813A3

    专利类型

  • 公开/公告日2003-01-16

    原文格式PDF

  • 申请/专利权人 KAROLINSKA INNOVATIONS AB;CAO YIHAI;

    申请/专利号WO2001EP10090

  • 发明设计人 CAO YIHAI;

    申请日2001-08-31

  • 分类号C07K14/47;A61K38/17;A61K39/395;

  • 国家 WO

  • 入库时间 2022-08-21 23:56:05

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号